Bold claim: Nerves may be driving pancreatic cancer from the very start, not just after tumors have formed. And this is the part many researchers are just beginning to understand. The latest study shows that pancreatic cancer might begin to develop while nerves are already at work, reshaping how we think about early-stage disease and potential treatments.
What the researchers found
- Pancreatic cancer is notoriously hard to detect early and often resists standard therapies. Scientists have long known that nerves can assist cancer spread, but details about the earliest stages were unclear.
- In the lab of David Tuveson at Cold Spring Harbor Laboratory, postdoctoral researcher Jeremy Nigri explains perineural invasion: cancer cells traveling along nerves to reach new sites. This is a mechanism by which the disease can metastasize, or spread, within the body.
- The new work provides evidence that the nervous system is involved even before tumors become visible. Using high-tech 3D imaging, the team tracked interactions between cancer-associated fibroblasts (myCAFs) and nerve fibers inside developing pancreatic lesions.
What the researchers saw with 3D imaging
- Traditional 2D imaging can miss the bigger picture. When viewed in three dimensions, nerves form a dense, interconnected network weaving through lesions and wrapping around myCAFs. This contrasts sharply with the sparse dots seen in 2D pictures.
- The surprise was not just the presence of nerves, but how actively they participate in early cancer development by communicating with nearby cells.
A self-reinforcing cycle that fuels growth
- The study uncovered a feedback loop between myCAFs and nerves. MyCAFs emit signals that attract sympathetic nerve fibers, which are part of the body’s fight-or-flight system.
- These nerve fibers release norepinephrine, a neurotransmitter that binds to fibroblasts and triggers a rise in intracellular calcium. That calcium surge further activates myCAFs, promoting pre-cancerous growth and drawing in even more nerves.
- The loop strengthens over time, creating a pro-tumor environment long before a full-blown tumor appears.
Evidence that interrupting nerve signals can slow growth
- In experiments with mice (and human cells), blocking nerve activity disrupted the crosstalk. Using a neurotoxin to dampen sympathetic signaling resulted in less activated fibroblasts and about a 50% reduction in tumor growth in the tested models.
Implications for new therapies
- Because these early nerve–fibroblast interactions occur early, they offer a potential new target for therapy. Drugs already in use for other conditions, such as doxazosin, might be repurposed or combined with existing treatments like chemotherapy or immunotherapy to improve outcomes.
- The researchers emphasize that the next steps involve detailing how to block this crosstalk so that interventions can be developed and tested in clinical settings.
Why this matters for patients and researchers
- If nerves help kick off pancreatic cancer earlier than previously thought, screening and treatment approaches may shift toward early nerve–cell interactions as a therapeutic target.
- This work also highlights the value of advanced imaging techniques in revealing hidden biology that could change how we diagnose and treat the disease.
Controversy and open questions
- Some may question how broadly this early nerve involvement applies across different patients or pancreatic cancer subtypes. Does disrupting nerve signaling uniformly slow progression, or are there contexts where it’s less effective? What are the long-term effects of targeting the nervous system in cancer therapy? These questions invite discussion.
Bottom line
- The study suggests nerves actively shape pancreatic cancer development far earlier than recognized, through a self-perpetuating loop with fibroblasts. Blocking this early crosstalk could become a promising strategy to slow or halt disease progression, especially when combined with existing treatments. And this is the part most people miss: addressing the nervous system’s role might unlock new avenues for prevention and therapy that start before tumors are even detectable.
What do you think about targeting nerve–cell interactions as a cancer therapy? Are there potential risks or benefits you’d like to see explored in future studies?
